Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benvitimod Cream in Cutaneous T-Cell Lymphoma
NCT07658924Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jul 2026
- Primary completion
- Oct 2027
01
Overview
Phase 2, randomised, double-blind trial of Benvitimod Cream in cutaneous T-cell lymphoma (CTCL) (2 arms), sponsored by Peking University First Hospital. Primary endpoints: modified Severity-Weighted Assessment Tool at Week 24 and Pruritus Visual Analogue Scale at Week 24. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
Benvitimod Cream
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT07658924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07658924.